| Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non–small cell lung cancer J Luo, VL Martucci, Z Quandt, S Groha, MH Murray, CM Lovly, H Rizvi, ... Clinical Cancer Research 27 (18), 5131-5140, 2021 | 48 | 2021 |
| FDRestimation: flexible false discovery rate computation in R MH Murray, JD Blume F1000Research 10, 2021 | 15 | 2021 |
| Factors influencing precision medicine knowledge and attitudes R Chakravarthy, SC Stallings, M Williams, M Hollister, M Davidson, ... PloS one 15 (11), e0234833, 2020 | 14 | 2020 |
| FDRestimation: estimate, plot, and summarize false discovery rates M Murray, J Bloom R Package 1 (1), 2022 | 6 | 2022 |
| False discovery rate computation: Illustrations and modifications MH Murray, JD Blume arXiv preprint arXiv:2010.04680, 2020 | 6 | 2020 |
| Racial disparities in lung cancer stage of diagnosis among adults living in the southeastern United States J Richmond, MH Murray, CM Milder, JD Blume, MC Aldrich Chest 163 (5), 1314-1327, 2023 | 2 | 2023 |
| Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis P Middha, R Thummalapalli, MJ Betti, L Yao, Z Quandt, K Balaratnam, ... Nature Communications 15 (1), 2568, 2024 | | 2024 |
| Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease in patients with multiple sclerosis initiating disease-modifying therapies: Retrospective cohort … AJM Brnabic, SE Curtis, JA Johnston, A Lo, AJ Zagar, I Lipkovich, ... Plos one 19 (3), e0300708, 2024 | | 2024 |
| A unified Bayesian framework for interval hypothesis testing in clinical trials A Chakraborty, MH Murray, I Lipkovich, Y Du arXiv preprint arXiv:2402.13890, 2024 | | 2024 |
| Genetic prediction of colitis in non-small cell lung cancer patients on immune checkpoint inhibitor therapy. P Middha, R Thummalapalli, MJ Betti, Z Quandt, K Balaratnam, ... Medrxiv: the Preprint Server for Health Sciences, 2023 | | 2023 |
| Evaluating the Intersectionality of Race and Gender in Lung Screening Eligibility in the 2021 United States Preventive Services Task Force Lung Screening Guidelines A Manful, MH Murray, G Smith, S Mercaldo, JD Blume, MC Aldrich A19. LUNG CANCER SCREENING: WHERE THE RUBBER MEETS THE ROAD, A1057-A1057, 2023 | | 2023 |
| Abstract A106: Are we there yet? Performance of risk-model based eligibility for lung cancer screening AA Manful, MH Murray, SF Mercaldo, JD Blume, MC Aldrich Cancer Epidemiology, Biomarkers & Prevention 32 (1_Supplement), A106-A106, 2023 | | 2023 |
| On second-generation p-values for equivalence testing and study planning, and flexible false discovery rate computation for classical p-values MH Murray | | 2022 |
| Disentangling Racial Disparities in Lung Cancer Stage of Diagnosis J Richmond, M Hollister Murray, CM Milder, JD Blume, MC Aldrich A109. THE ODYSSEY, NO LONGER A TRAGEDY: THE CONTINUUM OF LUNG CANCER, A2343 …, 2022 | | 2022 |
| Abstract PO-236: Examining racial disparities in lung cancer stage of diagnosis among low-income adults living in the southeastern US J Richmond, M Hollister, CM Milder, AG Schwartz, JD Blume, MC Aldrich Cancer Epidemiology, Biomarkers & Prevention 31 (1_Supplement), PO-236-PO-236, 2022 | | 2022 |
| FDRestimation: Flexible False Discovery Rate Computation in R [version 1; peer review: awaiting peer review] MH Murray, JD Blume | | 2021 |
| Properties of machine learning and FDRs for discovery in large scale data MH Murray | | 2020 |
| False Discovery Rate Computation: Illustrations and Modifications M Hollister Murray, JD Blume arXiv e-prints, arXiv: 2010.04680, 2020 | | 2020 |
| 4497 Accessible False Discovery Rate Computation MC Hollister, JD Blume Journal of Clinical and Translational Science 4 (s1), 44-44, 2020 | | 2020 |
| An evaluation of machine learning and traditional statistical methods for discovery in large-scale data M Hollister | | 2019 |
Jeffrey D. BlumeUniversity of VirginiaVerified email at virginia.edu
